Evidence map›Paper›PMID 34192258›Full record

ReviewJAC-antimicrobial resistance2021

The potential impact of the COVID-19 pandemic on global antimicrobial and biocide resistance: an AMR Insights global perspective.

Shamshul Ansari, John P Hays, Andrew Kemp, Raymond Okechukwu, Jayaseelan Murugaiyan, Mutshiene Deogratias Ekwanzala, Maria Josefina Ruiz Alvarez, Maneesh Paul-Satyaseela, Chidozie Declan Iwu, Clara Balleste-Delpierre and 13 more

Abstract readReview
In one paragraph

Review in JAC-antimicrobial resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. A Seven-Year Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Epidemiological and Antimicrobial Resistance Trends ofInfection and drug resistance · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shamshul AnsariDepartment of Microbiology, Chitwan Medical College and Teaching Hospital, Bharatpur, 44200 Chitwan, Nepal.ORCID https://orcid.org/0000-0003-1846-1377
John P HaysDepartment of Medical Microbiology & Infectious Diseases, Erasmus University Medical Centre Rotterdam (Erasmus MC), Rotterdam, The Netherlands.
Andrew KempScientific Advisory Board of the British Institute of Cleaning Sciences, Northampton, UK.
Raymond OkechukwuDepartment of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Agulu Campus, Nigeria.
Jayaseelan MurugaiyanDepartment of Biology, SRM University AP, Andhra Pradesh 522502, India.
Mutshiene Deogratias EkwanzalaDepartment of Environmental, Water and Earth Sciences, Tshwane University of Technology, Pretoria, South Africa.
Maria Josefina Ruiz AlvarezResearch Coordination and Support Service, Istituto Superiore di Sanità, Rome, Italy.
Maneesh Paul-SatyaseelaAcharya Institute of Technology, Bengaluru, India.ORCID https://orcid.org/0000-0002-6702-4942
Chidozie Declan IwuSchool of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Clara Balleste-DelpierreISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Ed SeptimusDepartment of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, MA, 02215, Texas A&M College of Medicine, Houston, TX 77030, USA.
Lawrence MugishaCollege of Veterinary Medicine, Animal Resources & Biosecurity (COVAB), Makerere University, Kampala, Uganda.
Joseph FadareDepartment of Pharmacology and Therapeutics, College of Medicine, Ekiti State University, Ado-Ekiti, Nigeria.ORCID https://orcid.org/0000-0002-5641-1402
Susmita ChaudhuriTranslational Health Science and Technology Institute, Faridabad 121001, India.
Vindana ChibabhaiDepartment of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand, and Clinical Microbiology Laboratory, Charlotte Maxeke Johannesburg Academic Hospital, National Health Laboratory Service, Johannesburg, South Africa.
J M Rohini W W WadanambyDepartment of Microbiology, Lanka Hospital Diagnostics, Lanka Hospital 578, Elvitigala Mw, Colombo 05, Sri Lanka.
Ziad DaoudDepartment of Clinical Microbiology & Infection Prevention, Michigan Health Clinics-Saginaw, MI, USA and Department of Foundational Sciences, CMED-CMU, Mount Pleasant, MI, USA.
Yonghong XiaoState Key Laboratory for Diagnosis & Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 300013, China.
Thulasiraman ParkunanDepartment of Veterinary Physiology and Biochemistry, Faculty of Veterinary and Animal Sciences, Institute of Agricultural Sciences, Rajiv Gandhi South Campus, Banaras Hindu University, Mirzapur, Uttar Pradesh, India.
Yara KhalafDepartment of Epidemiology, High Institute of Public Health, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0002-8013-7140
Nkuchia M M'IkanathaDivision of Infectious Disease Epidemiology, Pennsylvania Department of Health, Harrisburg, PA, USA.ORCID https://orcid.org/0000-0002-5631-184X
Maarten B M van DongenAMR Insights, Amsterdam, The Netherlands.
Global AMR Insights Ambassador Network

Funding

FDA HHS U01 FD006253FDA HHS U01 FD007142
6 · The paper itself

Abstract

The COVID-19 pandemic presents a serious public health challenge in all countries. However, repercussions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on future global health are still being investigated, including the pandemic's potential effect on the emergence and spread of global antimicrobial resistance (AMR). Critically ill COVID-19 patients may develop severe complications, which may predispose patients to infection with nosocomial bacterial and/or fungal pathogens, requiring the extensive use of antibiotics. However, antibiotics may also be inappropriately used in milder cases of COVID-19 infection. Further, concerns such as increased biocide use, antimicrobial stewardship/infection control, AMR awareness, the need for diagnostics (including rapid and point-of-care diagnostics) and the usefulness of vaccination could all be components shaping the influence of the COVID-19 pandemic. In this publication, the authors present a brief overview of the COVID-19 pandemic and associated issues that could influence the pandemic's effect on global AMR.

Identifiers

PMID34192258
PMCPMC8083476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.